Accessibility StatementSkip Navigation SAN FRANCISCO and SUZHOU, China, Nov. 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, announced that pre-clinical study results of IBI3011 (IL-1RAP monoclonal antibody) and IBI3034 (TACI/BCMA chimeric fusion protein ...